Full Text of SB2060 96th General Assembly
SB2060sam002 96TH GENERAL ASSEMBLY
|
Sen. Dan Kotowski
Filed: 3/15/2010
|
|
09600SB2060sam002 |
|
LRB096 11300 ASK 38943 a |
|
| 1 |
| AMENDMENT TO SENATE BILL 2060
| 2 |
| AMENDMENT NO. ______. Amend Senate Bill 2060 by replacing | 3 |
| everything after the enacting clause with the following:
| 4 |
| "Section 5. The Pharmacy Practice Act is amended by | 5 |
| changing Section 25 as follows: | 6 |
| (225 ILCS 85/25) (from Ch. 111, par. 4145) | 7 |
| (Section scheduled to be repealed on January 1, 2018) | 8 |
| Sec. 25. No person shall compound, or sell or offer for | 9 |
| sale, or
cause to be compounded, sold or offered for sale any | 10 |
| medicine or preparation
under or by a name recognized in the | 11 |
| United States Pharmacopoeia
National Formulary, for internal | 12 |
| or external use, which differs from
the standard of strength, | 13 |
| quality or purity as determined by the test
laid down in the | 14 |
| United States Pharmacopoeia National Formulary official at
the | 15 |
| time
of
such compounding, sale or offering for sale. Nor shall | 16 |
| any person
compound, sell or offer for sale, or cause to be |
|
|
|
09600SB2060sam002 |
- 2 - |
LRB096 11300 ASK 38943 a |
|
| 1 |
| compounded, sold,
or offered for sale, any drug, medicine, | 2 |
| poison, chemical or pharmaceutical
preparation, the strength | 3 |
| or purity of which shall fall below the professed
standard of | 4 |
| strength or purity under which it is sold. Except as set forth | 5 |
| in Section 26 of this Act, if the physician
or other authorized | 6 |
| prescriber, when transmitting an oral or written
prescription, | 7 |
| does not prohibit drug product selection, a different
brand | 8 |
| name or nonbrand name drug product of the same generic name may
| 9 |
| be dispensed by the pharmacist, provided that the selected drug
| 10 |
| has
a unit price less than the drug product specified in the | 11 |
| prescription.
A generic drug determined to be therapeutically | 12 |
| equivalent by the
United States Food and Drug Administration | 13 |
| (FDA) shall be
available for substitution in Illinois in | 14 |
| accordance with this
Act and the Illinois Food, Drug and | 15 |
| Cosmetic Act, provided that
each manufacturer submits to the | 16 |
| Director of the Department of Public Health a notification | 17 |
| containing product
technical bioequivalence information as a | 18 |
| prerequisite to product
substitution when they have completed | 19 |
| all required testing to
support FDA product approval and, in | 20 |
| any event, the information
shall be submitted no later than 60 | 21 |
| days prior to product
substitution in the State.
On the | 22 |
| prescription forms of prescribers,
shall be placed a signature | 23 |
| line and the words
"may not substitute". The prescriber, in his | 24 |
| or her own handwriting,
shall place a mark beside "may not | 25 |
| substitute"
to direct
the pharmacist in the dispensing of the | 26 |
| prescription.
Preprinted or rubber stamped marks, or other |
|
|
|
09600SB2060sam002 |
- 3 - |
LRB096 11300 ASK 38943 a |
|
| 1 |
| deviations from
the above prescription format shall not be | 2 |
| permitted. The prescriber
shall sign the form in his or her own | 3 |
| handwriting to authorize the
issuance of the prescription. If a | 4 |
| pharmacist substitutes any prescription, then the pharmacist | 5 |
| shall provide written notice to the patient. | 6 |
| In every case in which a selection is made as permitted by | 7 |
| the Illinois
Food, Drug and Cosmetic Act, the pharmacist shall | 8 |
| indicate on the pharmacy
record of the filled prescription the | 9 |
| name or other identification
of the manufacturer of the drug | 10 |
| which has been dispensed. | 11 |
| The selection of any drug product by a pharmacist shall not | 12 |
| constitute
evidence of negligence if the selected nonlegend | 13 |
| drug product was of
the same dosage form and each of its active | 14 |
| ingredients did not vary
by more than 1 percent from the active | 15 |
| ingredients of the prescribed,
brand name, nonlegend drug | 16 |
| product. Failure of a prescribing
physician to specify that | 17 |
| drug product selection is prohibited does not
constitute | 18 |
| evidence of negligence
unless that practitioner has reasonable | 19 |
| cause to believe that the health
condition of the patient for | 20 |
| whom the physician is prescribing warrants
the use of the brand | 21 |
| name drug product and not another. | 22 |
| The Department is authorized to employ an analyst or | 23 |
| chemist of recognized
or approved standing whose duty it shall | 24 |
| be to examine into any claimed
adulteration, illegal | 25 |
| substitution, improper selection, alteration,
or other | 26 |
| violation hereof, and report the result of his investigation,
|
|
|
|
09600SB2060sam002 |
- 4 - |
LRB096 11300 ASK 38943 a |
|
| 1 |
| and if such report justify such action the Department shall | 2 |
| cause the
offender to be prosecuted. | 3 |
| (Source: P.A. 94-936, eff. 6-26-06; 95-689, eff. 10-29-07.)".
|
|